Simultaneous measurement of drug metabolic stability and identification of metabolites using ion‐trap mass spectrometry
- 5 November 2003
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 17 (23) , 2661-2668
- https://doi.org/10.1002/rcm.1228
Abstract
The use of in vitro drug metabolism data in the understanding of in vivo pharmacokinetic, safety and toxicity data has become a large area of scientific interest. This has stemmed from a trend in the pharmaceutical industry to use in vitro data generated from human tissue as a criterion to select compounds for further investigation. As well as measuring metabolic stability in vitro using human liver microsomal preparations, the identification of possible metabolite(s) formed may play a vital role in Hit-to-Lead and Lead optimisation processes. The data-dependent scan function mode with the ion-trap instrumentation provides the ability to measure the metabolic stability and identification of possible metabolites of a compound. A gradient liquid chromatographic method with a run time of 6 min/injection was developed for this purpose. The approach of simultaneous metabolic stability measurements and rapid identification of metabolites of drugs with high (verapamil), medium (propranolol and cisapride) and low (flunarazine) metabolic stabilities using ion-trap mass spectrometry is described. The metabolites identified after 15 min incubation for verapamil, propranolol and cisapride are in good agreement with those reported as the major metabolites in human in vivo studies. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- On-Line Liquid Chromatography-Accurate Radioisotope Counting Coupled with a Radioactivity Detector and Mass Spectrometer for Metabolite Identification in Drug Discovery and DevelopmentAnalytical Chemistry, 2003
- High-Throughput Proteomics: A Flexible and Efficient Pipeline for Protein ProductionJournal of Proteome Research, 2002
- Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parametersBioorganic & Medicinal Chemistry Letters, 2002
- The impact of genomics on anti-infectives drug discovery and developmentTrends in Microbiology, 2002
- Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography–mass spectrometryJournal of Chromatography A, 2002
- Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery processRapid Communications in Mass Spectrometry, 2002
- An intelligent data acquisition system for simultaneous screening of microsomal stability and metabolite profiling by liquid chromatography/mass spectrometryJournal of Mass Spectrometry, 2001
- Proteomics: delivering new routes to drug discovery – Part 1Drug Discovery Today, 2001
- Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents*Clinical Pharmacology & Therapeutics, 1997
- Guidelines for Antiepileptic Drug Trials in ChildrenEpilepsia, 1994